Alexandra Martínez-Roca: At-Home (AH) care program for AML patients undergoing induction therapy with VenAza
Alexandra Martínez-Roca , Hematologist at Hospital Clinic, shared on X:
“Thrilled to share our latest study: ‘At-Home (AH) care program for Acute Myeloid Leukemia (AML) patients undergoing induction therapy with Venetoclax + Azacitidine (VenAza)’
The Challenge
VenAza, despite being a low-intensity regimen, often leads to severe cytopenias and infections, traditionally requiring hospitalization. Could this high-risk induction phase be safely managed at home?
Study Design
From 2019–2022, we studied 70 AML patients:
•26 treated in the hospital
•44 enrolled in our AH program
AH patients met strict criteria: stable WBC counts, no active infections, close proximity to the hospital, and caregiver support.
What We Found
•AH patients had 65% fewer hospital readmissions (29.5% vs. 84.6%, p < 0.001).
•Shorter hospital stays (8 vs. 13 days).
•Comparable safety outcomes (e.g., febrile neutropenia, infection rates).
No cases of tumor lysis syndrome (TLS) were observed.
The AH Model Works
Our program combined:
•Home-based therapy administration
•Comprehensive patient/caregiver education
•Continuous monitoring and rapid AE management via a 24/7 support unit
This reduced healthcare resource use while improving patient and caregiver comfort.
Conclusion
Our AH program for VenAza-treated AML patients is:
•Safe
•Effective
•Patient-friendly
This approach could redefine leukemia care, especially for patients undergoing low-intensity regimens.“
Authors: Alexandra Martínez-Roca et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023